Becker's Healthcare February 16, 2024
Paige Twenter

A week ahead of schedule, the FDA approved the nation’s first cell therapy for advanced melanoma on Feb. 16.

The drug, Iovance Biotherapeutics’ Amtagvi, is a tumor-derived autologous T cell immunotherapy that expands a patient’s own T cells to fight the cancer.

The medicine is indicated for unresectable or metastatic melanoma, which...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Pharma Pulse 3/14/25: Navigating Internal Constraints and Uncertainty, Health Plan Support During Natural Disasters & more
New AI model can estimate a person's true biological age from five drops of blood
Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal
FDA Approves First Biosimilar to Omalizumab
Zealand Pharma, Roche Reach Potential $5.3 Billion Deal to Develop Petrelintide for Weight Management

Share This Article